{"organizations": [], "uuid": "9686da472024d1479040e52dd5cbb7165dfffb00", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180529.html", "section_title": "Archive News &amp; Video for Tuesday, 29 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novimmune-fda-accepts-emapalumab-b/brief-novimmune-fda-accepts-emapalumab-biologics-license-application-with-priority-review-idUSFWN1SZ00R", "country": "US", "domain_rank": 408, "title": "BRIEF-Novimmune: FDA Accepts Emapalumab Biologics License Application With Priority Review", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.44, "site_type": "news", "published": "2018-05-28T13:08:00.000+03:00", "replies_count": 0, "uuid": "9686da472024d1479040e52dd5cbb7165dfffb00"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novimmune-fda-accepts-emapalumab-b/brief-novimmune-fda-accepts-emapalumab-biologics-license-application-with-priority-review-idUSFWN1SZ00R", "ord_in_thread": 0, "title": "BRIEF-Novimmune: FDA Accepts Emapalumab Biologics License Application With Priority Review", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "novimmune sa", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 28 (Reuters) - Novimmune SA ( IPO-NOVI.S ):\n* FDA ACCEPTS EMAPALUMAB BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW Source text: bit.ly/2lagxU7 Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://bit.ly/2lagxU7", "https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://www.youtube.com/user/ReutersVideo", "https://instagram.com/reuters/"], "published": "2018-05-28T13:08:00.000+03:00", "crawled": "2018-05-30T11:14:19.006+03:00", "highlightTitle": ""}